AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00392015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
Description: Malaria Vaccines
Study NCT00645112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: oral suspension, 7 mg/kg every 12 hours for 5 days
Study NCT00645112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
Study NCT03796910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 for SAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
Study NCT03796910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
Study NCT03796910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 for MAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
Study NCT03796910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
Study NCT02727270 — intervention group
Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study
Study NCT00608595 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: not noted
Study NCT00228306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise
Description: Rehab therapy is delivered for 8 weeks.
Study NCT00608595 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Not noted
Study NCT00608595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: not noted
Study NCT00608595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: not noted
Study NCT00608595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study NCT00608595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
Study NCT02501447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided audio-visual relaxation
Study NCT04049357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camera Capsule Endoscopy/ PillCam
Description: Camera Capsule Endoscopy in screening
Study NCT03693300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
Study NCT02598804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 educational workshop
Study NCT02598804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: written information booklet
Study NCT02074644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic Arterial Embolization
Description: The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way.
Study NCT02074644 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
Study NCT02173223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor
Study NCT00686283 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEP intervention
Description: This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
Study NCT00150709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use
Study NCT01261806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up
Description: Enhances nurturance, following the lead, and calming behaviors
Study NCT01261806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Attention control: Enhances parents understanding of developmental milestones
Study NCT02141802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doubling standing time
Description: Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
Study NCT02141802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
Study NCT01758666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate,Calcium folinate
Study NCT04434820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External negative pressure dressing system (Yuwell 7E-A portable suction unit)
Description: A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
Study NCT01446601 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
Description: The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
Study NCT01130467 — intervention group
Intervention type: DRUG
Intervention: Atomoxetine
Description: Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
Study NCT00608595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: not noted
Study NCT00608595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: not noted
Study NCT04332848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET
Description: Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
Study NCT04332848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGT
Description: Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
Study NCT01800526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Oral and Intravenous administration of NAC
Study NCT03438539 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Normative Feedback
Description: Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
Study NCT01130467 — intervention group
Intervention type: BEHAVIORAL
Intervention: behavioral modification
Description: Parenting and teaching skill education
Study NCT01551056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study NCT01551056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study NCT02073123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~* If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~* If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~* If > 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~* If >1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If >1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1
Study NCT02073123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
Study NCT02073123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered intravenously at 240 mg every 2 weeks.
Study NCT02073123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
Study NCT00131144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate in Microspheres 20 mg
Study NCT01446601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
Description: The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
Study NCT00153894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
Study NCT00131144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate in Microspheres
Study NCT00131144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02550197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016
Description: 0.5 mL, Intramuscular
Study NCT02550197 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
Description: 0.5 mL, Intramuscular
Study NCT00795054 — intervention group
Intervention type: OTHER
Intervention: Household financial data collection
Description: Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
Study NCT02345018 — intervention group
Intervention type: PROCEDURE
Intervention: Mechano-chemical ablation
Description: Treatment with mechano-chemical ablation
Study NCT01891279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elemental formula Elecare®
Description: Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
Study NCT01891279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partially hydrolyzed formula
Description: Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
Study NCT02882347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Study NCT00153894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
Study NCT03766802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable watch training group.
Description: 3 orientation session Watch notifies 3/week for exercise
Study NCT03766802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application training group.
Description: 3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise.
Study NCT03766802 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Supervised exercise training group
Description: 3/week training supervised by a physical therapist
Study NCT02428452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social ABCs parent-mediated intervention program
Description: The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
Study NCT03722784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invigor A (test)
Description: silicone hydrogel lens
Study NCT03722784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invigor B (control)
Description: silicone hydrogel lens
Study NCT02038218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Demethyl-4-cholestryloxycarbonylpenclomedine
Description: This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance.
Study NCT00634452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1401
Description: IV weekly for 4 weeks
Study NCT00773084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
Description: Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
Study NCT00724763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: to Liv 3 and PE 9.
Study NCT00724763 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham needle treatment
Description: needle not in meridian area
Study NCT04015804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical database
Description: Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
Study NCT02566863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
Study NCT04128358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological assay for blood born viral hepatitis
Description: Qualitative PCR for patients with hepatitis C antibody positive
Study NCT04128358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serological assay for blood born viral hepatitis
Description: Qualitative PCR for patients with hepatitis C antibody positive
Study NCT04128358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Serological assay for blood born viral hepatitis
Description: Qualitative PCR for patients with hepatitis C antibody positive
Study NCT04128358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative microbiological test for HCV
Description: Quantitative PCR in those with proven HCV infection
Study NCT04128358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative microbiological test for HCV
Description: Quantitative PCR in those with proven HCV infection
Study NCT04128358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Quantitative microbiological test for HCV
Description: Quantitative PCR in those with proven HCV infection
Study NCT02389777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266 immediate
Description: ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
Study NCT02389777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266 delayed
Description: ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
Study NCT04558788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry on intestinal biopsies
Description: Immunohistochemistry will be performed on human intestinal biopsies
Study NCT03216317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Isometric handgrip training consisting of four series
Study NCT05534204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silk suture
Description: Patients with bilateral impacted lower third molars will have operations for both sides. On one side for primarily closure after operation silk suture will be used.
Study NCT05534204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polyester suture
Description: Patients with bilateral impacted lower third molars will have operations for both side. On one side for primarily closure after operation polyester suture will be used.